Home » FightingDrugFailure » Visiting Scientist

Visiting Scientist

VC Jordan, OBE, PhD, DSc, a highly experienced and distinguished USA/UK researcher, has supported the ITN supervisory board and has taken an active part in the conception and organization of training and showcase events. Professor V. Craig Jordan is a pioneer in the discovery of the breast cancer prevention properties of tamoxifen and the scientific principles of adjuvant therapy with antihormones. Tamoxifen is a selective estrogen receptor modulator (SERM) used to treat millions of breast cancer patients. As the “Father of Tamoxifen”, Professor Jordan has conceptually shaped the development and clinical application of tamoxifen as an anti-breast cancer drug for over thirty years. His current work deals with unraveling the molecular basis of drug resistance to selective estrogen receptor modulators. His research has recently expanded to the use of SERMs in the prevention of multiple diseases in women and in particular, osteoporosis. His successful career in drug development, treatment outcome and clinical implementation make him a foremost expert to motivate and improve skills and know-how of young investigators in Pharmacogenomics.

He has earned numerous awards and distinctions, and he is the recipient of the following, among others:

The 2012 Louis S. Goodman and Alfred Gilman Award in Drug Receptor Pharmacology for outstanding research in pharmacology of biological receptors.

The 2011 St. Gallen Prize for Clinical Breast Cancer Research.

The 2008 ASCO Karnofsky Award, a top prize in medical oncology, for changing the practice of oncology.

The British Royal Society of Medicine Honorary Fellowship, the highest award in British Medicine.

 

 

 

Professor Virgil Craig Jordan

  • Scientific Director, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, Vincent T. Lombardi Chair of Translational Cancer Research
  • Vice Chairman, Department of Oncology Georgetown University Medical School
  • Professor of Oncology and Pharmacology, Georgetown University Medical School
  • Visiting Professor of Molecular Medicine, University of Leeds, England
  • Adjunct Professor of Molecular Pharmacology and Biological Chemistry, NW University, Chicago

Professional Recognition

Election to Meritorious Professional Societies

  • Fellow of the AACR Academy 2013 (USA)
  • National Academy of Sciences, 2009 (USA)
  • Fellow of the Academy of Medical Sciences, 2009 (UK)
  • Fellow of the Society of Biology, 2009 (Formerly the Institute of Biology) (UK)

Major National and International Awards

  • Bristol Myers Squibb Award and Medal for Distinguished Achievement in Cancer Research, 2001
  • American Cancer Society Medal of Honor (Basic Research Award), 2002
  • Officer of the Most Excellent Order of the British Empire (OBE) for services to International Breast Cancer Research, 2002
  • The Charles F. Kettering Prize of the General Motors Cancer Research Foundation. For the most outstanding recent contribution to cancer treatment, 2003

Professional Societies

American Association for Cancer Research

  • Eighth Bruce F. Cain Memorial Award (with L.J. Lerner) for outstanding preclinical research in cancer chemotherapy, 1989
  • Inaugural Dorothy P. Landon AACR Prize in Translational Research (with E.V. Jensen) for extraordinary accomplishment in translational research, 2002
  • Inaugural Class of Fellows of the AACR Academy, 2013
    The inaugural class of Fellows of the AACR Academy consists of 106 individuals, symbolizing the age of the organization upon establishment of the academy.

American Society for Pharmacology and Experimental Therapeutics

  • ASPET Award for Experimental Therapeutics. Contributions to research on human disease, 1993

American Society of Clinical Oncology

  • American Cancer Society Award for Chemoprevention. Recognizes translational research with tamoxifen and raloxifene to advance healthcare through clinical trials, 2006
  • 38th David A. Karnofsky Award. Recognizes clinical research that has changed the practice of oncology, 2008

British Pharmacological Society

    • City and Guilds Institute (London UK) - Elected to Fellowship 2013
    • Gaddum Memorial Award for research contributions to pharmacology, 1993

    North American Menopause Society

    • North American Menopause Society/Eli Lilly SERM Research Award. Recognizes research in any area including osteoporosis. Development of raloxifene and SERM action, 2003

    Royal Pharmaceutical Society of Great Britain

    • Elected Honorary Member for distinguished service to therapeutics with the development of tamoxifen and raloxifene, 2008

    Royal Society of Chemistry

    • Third George and Christine Sosnovsky Award in Cancer Therapy. Recognizes landmark achievements in the medicinal chemistry of cancer diseases, 2003-4

    Royal Society of Medicine

    • Honorary Fellowship of the Royal Society of Medicine. This is considered to be the highest honor in medicine in the United Kingdom. The award recognizes the pioneering work that led to the development of both tamoxifen and raloxifene, 2008. (see page 14)
    • The Jephcott Medal. Recognizes advances in the treatment and prevention of breast cancer, 2009.

    Academic Institutions

    • Cameron Prize for Therapeutics. Practical contribution to the treatment of human disease. (see page 13) Edinburgh University Medical School, Scotland, 1993
    • Herbert J. Block Memorial Award for Distinguished Achievement in Cancer from The Ohio State University, Responsible for advances in the use of tamoxifen in treating and preventing breast cancer. 1996
    • Honorary Fellowship Award and medal of the Faculty of Medicine of University College, Dublin, Ireland. Contribution to medicine with the development of tamoxifen and raloxifene, 2000
    • Strang Award for outstanding contributions to the field of cancer prevention. Strang Cancer Prevention Center, Cornell Medical School, New York, New York, 2000
    • Honorary Doctor of Science Degree. The award recognizes the development of tamoxifen for the treatment and prevention of breast cancer. University of Massachusetts, 2001
    • Honorary Doctor of Medicine Degree. The award recognizes humanitarian research in medicine that has improved healthcare. University of Leeds, England 2001
    • Honorary Doctor of Science Degree. The award recognizes the development of tamoxifen and raloxifene. University of Bradford, England, 2005
    • Honorary Professor and Medal of Merit, University of Iguacu, Rio de Janeiro, Brazil, 2005
    • Gregory G. Pincus Award and Medal (with Angela Brodie). The award recognizes contribution to the endocrine treatment and prevention of breast cancer. Worcester Foundation for Biomedical Research/University of Massachusetts Medical School, 2007
    • Honorary Doctor of Medicine Degree. The award recognizes the development of tamoxifen and raloxifene University of Crete, Greece 2009
    • Tamoxifen Team honored on the "Wall of Honour" at the Royal Society of Medicine headquarters (London) 2013

    National and International Groups

    • First Brinker International Breast Cancer Award for Basic Science. Outstanding research contributions toward the development of tamoxifen as a breast cancer therapy and preventive, Susan G. Komen Foundation, Dallas, 1992 Award presented in the presence of the Vice President of the United States of America
    • William L. McGuire Memorial Award. Contributions to breast cancer research. San Antonio Breast Cancer Symposium. Texas, 1994
    • Twelfth Award for Scientific Excellence in Medicine. Outstanding research contributions to chemoprevention. American-Italian Foundation for Cancer Research, New York, 1995
    • Laureate of the 6th Cino del Duca Award for Oncology. Award based on research that led to the clinical development of tamoxifen for the treatment and prevention of breast cancer. Paris, France, 1997
    • Third Annual Breast Cancer Award. Recognizes a lifetime of achievement in breast cancer research. European Institute of Oncology, Milan, Italy, 2001. Award presented by Professor Umberto Veronesi Italian Health Minister
    • Vivian and Meyer P. Potamkin Foundation Award for Breast Cancer Research. Recognizes the role of tamoxifen in saving women’s lives. Pennsylvania Breast Cancer Coalition, Harrisburg, Pennsylvania, 2001
    • Pennsylvania Breast Cancer Coalition Pink Ribbon Award. Presented to outstanding individuals dedicated to finding a cure for breast cancer. Pennsylvania Breast Cancer Coalition, Harrisburg, Pennsylvania, 2001
    • Avon Medical Advancement Award. Tamoxifen. Avon Foundation. Lincoln Center, New York, NY. 2002
    • Miami Breast Cancer Conference Award of Excellence. The definition of the scientific principles for the clinical development of tamoxifen and raloxifene. 2003
    • AstraZeneca Historical Milestones Excellence Award. Scientific principles for the clinical development of tamoxifen. San Antonio Breast Cancer Conference. 2003
    • National Breast Cancer Awareness Month (NBCAM) Award For outstanding contributions to advances in breast cancer treatment and prevention, New York, NY. 2004
    • Honorary Member Brazilian Society of Mastology. 2005
    • Honor of Merit, Institute du Mammado, Rio Grande do Sul, Brazil. "Recognition of the Brazilian women for the development of tamoxifen which brought hope and cure for millions of patients". 2005
    • American Cancer Society Southeast Region Pennsylvania Division Scientific Research Award For outstanding accomplishments in translational research 2007

    Membership on Prize Committees

    • Dr. Josef Steiner Cancer Research Prize, Bern, Switzerland, 1992
    • Brinker International Award for Breast Cancer Susan G. Komen 1998-2004
    • Dorothy P. Landon-AACR Prize for Translational Cancer Research, American Association for Cancer Research, 2003
    • Pezcoller Foundation-AACR International Award for Cancer Research, American Association for Cancer Research, 2006
    • Sheikh Hamdan bin Rashid Al Maktoum Award (Therapy and Malignancy), UAE University, United Arab Emirates, 2007
    • AACR Outstanding Investigator Award for Breast Cancer Research, American Association for Cancer Research, 2009
    • AACR Lifetime Achievement Award, American Association for Cancer Research, 2009
    • Luigi Castagnetta Award, University of Palermo, Italy, 2009

    Education

    • 1969
      Department of Pharmacology, University of Leeds, England, Bachelor of Science with Honors Class I
    • 1973
      Doctor of Philosophy (Pharmacology), University of Leeds, England Thesis title: "A study of the oestrogenic and antioestrogenic activities of some substituted triphenylethylenes and triphenylethanes." Examiner: Dr. A. L. Walpole (patent holder of ICI46,474 (tamoxifen))
    • 1973 (July)
      National Cancer Institute sponsored training program in estrogen receptors and breast cancer. Leave of absence to study techniques with Dr. E.V. Jensen (then Director Ben May Cancer Laboratories, Chicago, Illinois, U.S.A.) and Dr. W.L. McGuire (Division of Medical Oncology, University of Texas, San Antonio, Texas, U.S.A.)
    • 1972 - 1973
      Research Associate, Worcester Foundation for Experi­mental Biology, Shrewsbury, Massachusetts 01545. Prostaglandins and reproductive endocrinology, antiestrogens and breast cancer.
    • 1985
      Doctor of Science degree (University of Leeds, England). Award made by examination for scientific contribution to "The pharmacology of non-steroidal antioestrogens."

    Academic Positions Held

    • 1973 - 74 Visiting Scientist, Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts, U.S.A. 01545
    • 1973 Lecturer in Pharmacology (part-time) Clark University, Worcester, Massachusetts, U.S.A.
    • 1974 - 79 Lecturer in Pharmacology, University of Leeds, Tenure, 1977
    • 1977 Visiting Investigator, (3 month sabbatical) Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, U.S.A.
    • 1979 - 80 Head, Endocrinology Unit, Ludwig Institute for Cancer Research, University of Berne, Inselspital, Berne, Switzerland (1-year appointment to design the laboratory facilities)
    • 1980 - 81 Assistant Professor of Human Oncology and Pharmacology, University of Wisconsin
    • 1981 - 85 Associate Professor of Human Oncology and Pharmacology, University of Wisconsin (Tenure-1981).
    • 1985 - 93 Professor of Human Oncology and Pharmacology, University of Wisconsin
    • 1993 - 95 Visiting Professor of Human Oncology, University of Wisconsin
    • 1993 - 04
      Professor of Cancer Pharmacology, Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois
    • 1994 - 04 Professor of Molecular Pharmacology and Biological Chemistry, Department of Pharmacology, Northwestern University Medical School, Chicago, Illinois.
    • 2003 - 04 Professor of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.
    • 2005 - 2009 Adjunct Professor of Cancer Biology, Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA.
    • 2006 - 2009 Adjunct Professor of Pharmacology, Temple University, Philadelphia PA

    Administrative Appointments in Cancer Centers

    • l981 - 87
      Head, University of Wisconsin Clinical Cancer Center (UWCCC) Pharmacology Group
    • 1983 - 93
      Director, Cancer Center Steroid Hormone Receptor Laboratory (UWCCC)
    • 1987 - 93
      Director, UWCCC Breast Cancer Research and Treatment Program
    • 1993 - 96
      Associate Director for Cancer Prevention and Control, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois
    • 1993 - 04
      Director, Lynn Sage Breast Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern Medical School, Chicago, Illinois
    • 2005 - 08
    • Vice President and Research Director for Medical Sciences, Fox Chase Cancer Center, Philadelphia, Pennsylvania
    • 2009 –
      present Scientific Director at the Lombardi Comprehensive Cancer Center, Vice Chairman of the Department of Oncology, Georgetown University, Washington DC

    Scholarships and Academic Distinctions

    • 1965
      Senior Subject Prize for Zoology, Moseley Hall School
    • 1966
      Akroyd Senior Scholarship for Organic Chemistry and Biochemistry, University of Leeds
    • 1969 - 72
      Medical Research Council (MRC) Scholarship
    • 1972
      Selected as a MRC student representative for the Nobel Prize Winners' meeting in Lindau, West Germany
    • 1974
      Joint winner, Boston Obstetrical Society Prize, Boston, Massachusetts
    • 1981
      Awarded UICC International Cancer Research Technology Transfer Grant to study at the Department of Clinical Pharmacology, University of Berne, Switzerland
    • 1984
      H.I. Romnes Faculty Fellow, University of Wisconsin
    • 1984
      Fellow Royal Society of Chemistry
    • 1985 - 93
      Member of the Breast Cancer Task Force for the European School of Oncology, Milan, Italy
    • 1999 - 2004
      Endowed Chair; Diana, Princess of Wales Professor of Cancer Research, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois
    • 2000
      Selected to be one of the one hundred cancer researchers from throughout the world to sign the “Charter of Paris” to cure cancer. The event was attended and hosted by President Jacques Chirac of France
    • 2004
      Fellow of the British Pharmacological Society
    • 2005 - 09
      Endowed Chair: Alfred G. Knudson Chair in Cancer Research, Fox Chase Cancer Center, Philadelphia, PA

    Service on Boards for Professional Societies and Institutions

    1. Elected Board of Trustees, Worcester Foundation for Biomedical Research, Shrewsbury, Massachusetts, (1995 -1998)
    2. Elected Board of Trustees for the Worcester Foundation for Biomedical Research, University of Massachusetts Medical School, (1999-2002)
    3. Elected Board of Trustees for the Worcester Foundation for Biomedical Research, University of Massachusettes Medical School, (2002-2005)
    4. Member Board of Trustees, AACR Foundation, (2003 – present)
    5. Chairman, President’s Circle, AACR Foundation, (2003 – present)
    6. Award for outstanding fundraiser as Inaugural Chair (AACR) (2007)
    7. Elected Board of Directors for the AACR (2007-2010).

    Named or memorial Lectures

    • 1986 Lloyd E. Harris Lecturer (Smith-Kline Visiting Scientist). University of Oklahoma Health Sciences Center
    • 1987 Dr. Theodor Segal Memorial Lecture. Department of Medicine, University of Louisville. 1989 Bruce F. Cain Memorial Lecture. American Association for Cancer Research Annual Meeting. San Francisco, CA
    • 1992 Dr. Nathaniel Berlin Lecture in Biological Science. Northwestern Medical School, Chicago
    • 1993 William L. McGuire Memorial Symposium. San Antonio, Texas
    • 1993 Sir John Gaddum Memorial Lecture. British Pharmacological Society, Cambridge Meeting
    • 1993 Cameron Prize Lecture, University of Edinburgh
    • 1994 Addleman Memorial Lecture. Princess Margaret Hospital, Toronto, Ontario, Canada
    • 1994 Carmela Louise Riker Memorial Lecture. Oregon Health Sciences University, Portland, Oregon
    • 1994 Julia and Patricia Kingsbury Memorial Lecture. Yale University, New Haven, Connecticut
    • 1994 William L. McGuire Memorial Lecture. 17th Annual Breast Cancer Symposium, San Antonio, Texas
    • 1995 Stuart Hughes Lecture. 4th Nottingham International Breast Cancer Symposium, England
    • 1996 Harold P. Rusch Memorial Breast Cancer Lecture, University of Wisconsin, Madison
    • 1997 The Herbert J. Block Memorial Lecture, The Ohio State University
    • 1998 Dame Ella McKnight Memorial Lecture, Victorian Breast Cancer Consortium, Melbourne, Australia
    • 1998 Professor A. Borkowski Retirement Lecture, Institute Jules Bordet, Bruxelles, Beligum
    • 1998 B.J. Kennedy Lectureship, University of Minnesota, Minneapolis
    • 1999 Bernard Schwartz Lecture, Stevens Cancer Center, LaJolla, California
    • 1999 Dr. John Olsen Distinguished Lecture, Cooperstown, New York
    • 1999 Dr. Saul Gusberg Distinguished Lecture, Mount Sinai Hospital, New York
    • 2000 Allen and Lee Chao Lectureship in Cancer Research, Univeristy of California, Irvine
    • 2000 Sarah Hill Memorial Lecture, Hinsdale Hospital, Chicago, Illinois
    • 2000 Lacassagne Lecture, Centre A. Lacassagne, Nice, France
    • 2000 Honorary Faculty Award Lecture, University College, Royal College of Physicians, Dublin, Ireland
    • 2000 Dr. Daniel G. Miller Lecture, The Strang Cancer Prevention Center, New York
    • 2001 Dr. Henry Lemon Lecture in Breast Cancer, University of Nebraska, Omaha
    • 2001 Bristol Myers Squibb Award Lecture, Princeton, New Jersey
    • 2001 Opening Plenary Lecture, Japanese Breast Cancer Society Annual Meeting, Maebashi, Japan
    • 2001 European Institute of Oncology 3rd Annual Breast Cancer Award Lecture, Milan, Italy
    • 2001 50th Distinguished Breast Cancer Lecture, University of California, Berkley, California
    • 2002 Dorothy P. Landon Prize Lecture, American Association for Cancer Research Annual Meeting. San Francisco, CA
    • 2002 Dr. Eliahu Caspi Memorial Lecture in Chemical Biology, University of Massachusetts, Worcester
    • 2002 Gail Klein Garlove Memorial Lecture, Norton Hospital, Louisville, Kentucky
    • 2003 Dorothy P. Landon Prize Lecture at the Landon AACR Symposium, University of Miami, Florida
    • 2003 The Barret Cancer Center and School of Pharmacy Distinguished Lectures, University of Cincinnati
    • 2003 Charles F. Kettering Prize Lecture, National Institutes of Health, Bethesda, MD
    • 2003 Sosnovsky Award Lecture Series on behalf of the Royal Society of Chemistry at chemistry departments in Oxford, Cardiff, Manchester, York, Dundee and Imperial College, London, United Kingdom
    • 2004 Elkin Distinguished Investigator Cancer Lecture. Winship Cancer Institute, Emory University, Atlanta, GA
    • 2004 Pfizer Distinguished Lecture, McGill University, Montreal, Quebec, Canada
    • 2004 Nakamoto Distinguished Lecture in Chemistry, Marquette University, Milwaukee, WI
    • 2004 Ninth Annual Mavis P. Kelsey Lecture, Institute for Biosciences and Technology, The Texas A&M University System Health Science Center, Houston, TX
    • 2004 J. Walter Juckett Memorial Distinguished Lecture, University of Vermont Cancer Center, Burlington, VT
    • 2005 Helen Shingleton Memorial Lecture, Michigan State University, Lansing, MI
    • 2005 Robert L. Krigel Endowed lecture in translational research, Lankenau Hospital, Philadelphia, PA
    • 2005 Opening Plenary Lecture, AACR Annual Meeting, Anaheim, CA
    • 2005 Presidential Lecture, 3rd Congress of the World Society for Breast Health, Tokyo, Japan
    • 2005 Opening Plenary Lecture, XIII Annual Meeting at the Brazilian Society of Mastology
    • 2005 Invited address before the National Academy of Medicine (Brazil)
    • 2006 Opening Plenary Lecture, Japanese Breast Cancer Society Annual Meeting, Kanazawa, Japan
    • 2006 American Cancer Society Award Lecture for Chemoprevention, Annual Meeting, American Society of Clinical Oncology, Atlanta, GA
    • 2006 Festscrift for Professor Manfred Kaufmann, Chair, Department of Obstetrics and Gynaecology, Goethe University, Frankfurt, Germany
    • 2007 Leeds Institute for Molecular Medicine, Sydney Brenner Symposium, Leeds, United Kingdom
    • 2007 Gregory Pincus Memorial Award Lecture, Worcester Foundation for Biomedical Research, Worcester, MA
    • 2007 Keynote Address, Molecular Targets for Cancer Prevention, Diagnosis and Treatment, Lemesos, Cyprus
    • 2008 Keynote Opening Address, 8ème Biennale Monégasque de Cancérologie, Monte Carlo, Monaco
    • 2008 Lynn Sage Memorial Lecture, 10th Annual Lynn Sage International Symposium, Chicago
    • 2008 Inaugural Keynote Speaker at the University of Wisconsin Medicine Day
    • 2008 38th David A. Karnofsky Award Lecture, American Society of Clinical Oncology, Chicago
    • 2009 Keynote Address, Hormone and Cancer Symposium, Stuttgart, Germany
    • 2009 Jephcott Award lecture, Royal Society of Medicine, London, United Kingdom
    • 2009 Glenn Robins Award lecture, New York Cancer Society, New York, NY
    • 2009 Keynote Address IMPACT, Breast Cancer Meeting, Brussels, Belgium
    • 2009 Keynote Address, 29th Annual Meeting German Society of Senology, Dusseldorf, Germany
    • 2009 Opening Keynote Address, 2nd World Congress of Cancer, Beijing, China
    • 2009 Keynote Address, University of Iowa, Midwest Breast Cancer Symposium, Iowa City, Iowa
    • 2011 St. Gallen Prize for Clinical Breast Cancer Research, Switzerland
    • 2012 Louis S. Goodman and Alfred Gilman Award in Receptor Pharmacology, American Society for Pharmacology and Experimental Therapeutics

    Biographical Reference

    Marquis Who's Who in Frontier Science and Technology, 1984/85, 1986/87
    Marquis Who's Who in the World, 1984/85, 1987/88, 1990/91 2007/2008
    Marquis Who's Who in America, 1988/89, 1990/91, 1992/93, 1995/1996 (50th Anniversary Issue), 2007/2008
    Men of Achievement, 1985/86 (Cambridge, England)
    Strathmore’s Who’s Who Registry 2000/01 until the present (Westbury, New York)
    Marquis Who’s Who in Medical Administration 2007/8
    Marquis Who’s Who in Education 2007/8
    Marquis Who’s Who in Healthcare 2007
    Princeton Global Network 2010

    Membership of Professional Societies

    Great Britain

    British Pharmacological Society (1976) (Fellow 2004)
    Royal Society of Chemistry (1981) (Fellow 1984)
    Hon. Member Royal Pharmaceutical Society of Great Britain (2008)
    Hon. Fellow Royal Society of Medicine (2008)
    Fellow of the Academy of Medical Sciences (2009)
    Fellow of the Society of Biology (2009)

    U.S.A.

    American Association for Cancer Research (1981)
    Board of Trustees, AACR Foundation (2003-present)
    Inaugural Chairman, President’s Circle (2003-present)
    Board of Directors, AACR (2007-2010)
    Member Publications Committee (2007-2010)
    American Society for Pharmacology and Experimental Therapeutics (1981)
    Endocrine Society (1981)
    Fellow of the American Institute of Chemists (1982-93)
    Society for Surgical Oncology (1994)
    American Society of Clinical Oncology (2001)
    American Society for Biochemistry and Molecular Biology (2003)
    National Academy of Sciences (2009)

    Inaugural Class of Fellows of the AACR Academy (2013)

    Editorial Responsibilities to Journals

    Managing Editor of Cancer Letters, 1992-1997

    Editorial Boards

    American Journal of Cancer (Editor Lynda R. Wiseman) (2002-present)
    Breast Cancer Research (Editor-in-Chief, Professor Bruce Ponder, FRS) (2002-2004)
    Breast Cancer Research and Treatment (Editor-in-Chief, Marc E. Lippman, M.D.) (1985-present)
    British Journal of Pharmacology (Professor Alan North, FRS) (2003-2007)
    Cancer Genomics and Proteomics (2003-present)
    Cancer Research (Editor C. Croce, MD) (1989-1998)
    Cancer Letters (Editors Clayson, Shubik, Jordan and Sluyser)(1992-1998)
    Cancer Prevention Research (Editor-in-Chief , Scott M. Lippman, MD) (2008-present)
    Clinical Breast Cancer Treatment (Editor-in-Chief, George W. Sledge, Jr., M.D.) (2002-2007)
    Clinical Cancer Research (Editor, John Mendelsohn, M.D.) (1995-2005)
    Endocrinology (Editor K. Korach, Ph.D.) (1999-2002)
    European Journal of Cancer (Editor-in-Chief, Professor John Smyth) (1991-present)
    European Journal of Cancer and Clinical Oncology (Editor, Professor H.J. Tagnon) (until 1990)
    Hormone Molecular Biology and Clinical Investigation (Editor, Jorge Pasqualini, M.D., Ph.D.) (2009-present)
    Hormones and Cancer (Editor-in-Chief, Jonathan J. Li) (2009-present)
    International Journal of Oncology (Professor D. A. Spandidos) (1993-present)
    Journal of National Cancer Institute (Editor-in-Chief, Dr. B. S. Kramer) (1992-present)
    Journal of Steroid Biochemistry and Molecular Biology (Editor, Jorge Pasqualini, M.D., Ph.D.) (1986-present)
    Journal of Women’s Cancer (Editors-in-Chief, Dr. I. Russo & Dr. J. Russo) (2000-present)
    Molecular and Cellular Endocrinology (Managing Editor, B. A. Cooke, Ph.D.) (1989-1993)
    Molecular Aspects of Medicine (Professor Harold Baum).(1994-1997)

    Additional Information

    1. Honorary Director of Y-Me the National Organization for Breast Cancer Information and Support, headquartered in Chicago, Illinois, (1993 – present)
    2. NSABP Breast Cancer Prevention Trial. Committee on Recruitment and Compliance, (1993 – 1998)
    3. Member of the Scientific Advisory Board, Strang Clinic, New York, (1995 -1999)
    4. Member, Advisory Board of Directors of National Association of Breast Cancer Organizations (NABCO), New York, (1993-2004)
    5. Member of the Scientific Advisory Board for the NSABP, (1997 – 2000)
    6. Named as one of Crain’s Chicago Business Technology 100 (1997)
    7. Scientific Chairman, NSABP Protocol P2 Tamoxifen vs. Raloxifene for the Prevention of Breast Cancer, (1998-2006)
    8. Jordan Prize in Medicinal Chemistry established at Leeds University, England (1999)
    9. American Cancer Society, Biography (1999) http://www.cancer.org
    10. Institute for Scientific Information, Essential Science Indicators Biography (2000). Listed as one of the top twenty breast cancer research workers for the 1990s. http://esi-topics.com/breast-cancer/authors/b1a.html
    11. Encyclopedia Britannica Biography, (2000)
    12. Elected Honorary Trustee for the Worcester Foundation for Biomedical Research, (2005)
    13. Jordan Scholarship in Pharmacology established Leeds University Medical School (2006)
    14. LIMM Jordan Lectures established by Leeds University Medical School (2007)
    15. Chairman, Scientific Advisory Board, Leeds Institute of Molecular Medicine (2008)
    16. Craig Jordan, Lecture in Translational Lecture, established Oxford University (2013)

    Invited Lectures at National and International Meetings

    More than 300 lectures wordwide since 1975.

    Invited Lectures to Institutions

    More than 450 lectures worldwide since1972.

    Published Abstracts

    More than 500 abstracts since 1973.

    Important Published Abstracts

    Jordan, V.C. (1974) Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethyl benzanthracene (DMBA)-induced rat mammary carcinoma model. J. Steroid Biochem. 5:354.

    This is the first report that tamoxifen would prevent rat mammary carcinogenesis and blocked estradiol binding to the human estrogen receptor from breast tumours. The report is the first that started a systematic evaluation of the drug as a breast cancer therapy in America.

    Jordan, V.C., Glusman, J.E., Eckert S., Lippman M.E., Powles, T.J., Costa, A., Morrow, M., and Norton, L. (1998) Incident primary breast cancer are reduced by raloxifene: integrated data from multicenter, double blind, randomized trials in 12,000 postmenopausal women. Proceedings of the American Society of Clinical Oncology 17:122 (Abstract), 466.

    This report is the first presented of all the available data to support the hypothesis that raloxifene, a drug used to prevent osteoporosis, could reduce the incidence of breast cancer as a beneficial side effect. I was chairman of the raloxifene oncology advisory and adjudication board.

    Jordan, V.C., Glusman, J.E., Eckert, S., Lippman, M.E., Powles, T.J., Costa, A., Morrow, M., and Norton, L. (1998) Raloxifene reduces incident primary breast cancer: integrated data from multicenter double blind placebo controlled, randomized trials in postmenopausal women. Breast Cancer Res. Treat. 50:227 (Abstract 2).

    This is the final analysis of data from osteoporosis trials with raloxifene used to plan the Study of Tamoxifen And Raloxifene (STAR) for the prevention of breast cancer in high-risk postmenopausal women. I am a member of the STAR steering committee and I was invited by Dr. Norman Wolmark to be the Scientific Chairman of the trial.

    Bibliography of Publications

    Total of more than 600 books, refereed papers, chapters, and reviews.

    Journal Covers

    Cancer Research 9(10): 2525-2821, 1989. American Association for Cancer Research annual prize winners (8th Cain Memorial Award, V. Craig Jordan) 1989.

    Cancer Research 53(7): 1475-1718, 1993. Special recognition cover V. Craig Jordan.

    International Journal of Oncology 12(2), 1998. Special recognition cover V. Craig Jordan for accomplishments in Breast Cancer Research

    Cancer Research 61(15), 2001. Special recognition cover for selective estrogen receptor modulators and the receipt of the Bristol Myers Squibb Award and Medal for Distinguished Achievement in Cancer Research

    International Journal of Cancer 104:587-596, 2003. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer sells stably transected with ER alpha (Anna S. Levenson et al). Research article recognized on the front cover

    Cancer Research 63:7400-7406 2003. Distinct molecular confirmations of the estrogen receptor alpha complex exploited by environmental estrogens (David Bentram et al). Research article recognized on the front cover

    Molecular Cancer Therapeutics 6:2817-2827, 2007. Exemestane’s 17-hydroxylated metabolite exerts biological effects as an androgen. (Eric A. Ariazi et al). Research article recognized on the front cover

    Clinical Breast Cancer 8: 125-133, 2008. Low dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. (Swaby, R et al). Review article recognized on the front cover

    Clinical Cancer Research 14:3168-3176, 2008. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing surviving levels. (Lu M et al), Research article recognized on the front cover